osimertinib

an EGFR tyrosine kinase inhibitor

Also Known As:

AZD-9291; AZD-9291 mesylate; AZD9291; AZD9291 mesylate; N-(2-((2-(dimethylamino)ethyl)methylamino)-4-methoxy-5-((4-(1-methyl-1H-indol-3-yl)-2-pyrimidinyl)amino)phenyl)-2-propenamide; N-(2-((2-(dimethylamino)ethyl)methylamino)-4-methoxy-5-((4-(1-methyl-1H-indol-3-yl)-2-pyrimidinyl)amino)phenyl)-2-propenamide methanesulfonate (1:1); Tagrisso; mereletinib; mereletinib mesilate; mereletinib mesylate; osimertinib mesilate; osimertinib mesylate

Networked: 1710 relevant articles (333 outcomes, 330 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Ramalingam, Suresh S: 36 articles (06/2022 - 04/2015)
2.	Ahn, Myung-Ju: 22 articles (03/2022 - 04/2015)
3.	Cantarini, Mireille: 20 articles (06/2022 - 09/2014)
4.	Jänne, Pasi A: 20 articles (06/2022 - 04/2015)
5.	Ohe, Yuichiro: 18 articles (06/2022 - 04/2015)
6.	Yang, James Chih-Hsin: 18 articles (06/2022 - 04/2015)
7.	Nakagawa, Kazuhiko: 18 articles (04/2022 - 01/2017)
8.	Wu, Yi-Long: 18 articles (03/2022 - 01/2017)
9.	Okamoto, Isamu: 18 articles (11/2021 - 01/2017)
10.	Sun, Shi-Yong: 17 articles (01/2022 - 10/2016)

Related Diseases

1.	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 07/01/2022 - "The recently published FLAURA trial demonstrated that osimertinib has remarkable efficacy in front-line setting for non-small cell lung cancer (NSCLC). " 07/01/2020 - "Osimertinib has proven efficacy in EGFR T790M mutation-positive non-small cell lung cancer (NSCLC) patients; however, its benefits have not been evaluated in a real-world setting. " 01/01/2020 - "In the treatment of patients with advanced non-small cell lung cancer, Osimertinib significantly reduced the expression of serum MMP-7, MMP-9, improved the clinical benefit and quality of life of patients. " 01/01/2023 - "Osimertinib is recommended as the first-line treatment of advanced non-small cell lung cancer (NSCLC) in adults. " 01/01/2023 - "Acquired resistance is a major obstacle to the therapeutic efficacy of osimertinib in non-small-cell lung cancer (NSCLC). "
2.	Neoplasm Metastasis (Metastasis) 06/14/2022 - "In univariate and multivariate analyses, most distant metastases, including the brain and bone, were unrelated to the therapeutic efficacy of osimertinib, although liver metastasis and L858R mutation were independently associated with shorter PFS. " 01/01/2020 - "Standard-dose osimertinib (80 mg daily) obtained durable clinical remission for 16 months, and high-dose osimertinib (160 mg daily) further prolonged the survival of 9 months after leptomeningeal metastases (LM) occurring. " 01/01/2018 - "Osimertinib demonstrated clinically meaningful efficacy against CNS metastases, with a high DCR, encouraging ORR, and safety profile consistent with that reported previously. " 11/01/2020 - "This study explored whether treatment with osimertinib leads to improved overall survival (OS) for patients with EGFR-mutated NSCLC with leptomeningeal metastases (LM) compared with those not treated with osimertinib. " 06/14/2022 - "Osimertinib provided better clinical benefits than 1st- and 2nd-generation EGFR-TKIs for patients with EGFR-mutant NSCLC, particularly those with brain or bone metastases and exon 19 deletion; however, its efficacy against liver metastasis was remarkably attenuated. "
3.	Lung Neoplasms (Lung Cancer) 04/01/2022 - "The remarkable efficacy of osimertinib in non‒small cell lung cancer (NSCLC) with acquired T790M mutation has been widely documented in clinical trials and real-world practice. " 10/28/2023 - "Osimertinib, which was the best treatment targeting his lung cancer, was avoided due to history of SJS. " 03/01/2022 - "Osimertinib can be beneficial for patients with EGFR-positive lung cancer for both ocular and systemic control." 11/15/2018 - "Osimertinib-a third-generation EGFR-TKI-targets the T790M mutation and has demonstrated high efficacy against EGFR-mutated lung cancer. " 01/01/2018 - ": Overall, our data indicated robust antitumor efficacy of osimertinib against multiple HER2 aberrations in lung cancer, either as a single agent or in combination with JQ1. "
4.	Neoplasms (Cancer) 02/01/2022 - "Conclusions Osimertinib treatment is deemed to be cost-effective for NSCLC with LM patients, however, its use would significantly increase annual cancer spending." 11/01/2022 - "Importantly, the combination was effective in inhibiting the growth of osimertinib-resistant tumors in vivo. " 12/01/2020 - "Further, the (R)-9b and osimertinib combination was also effective in inhibiting the growth of EGFR mutant NSCLC cell lines with acquired resistance to osimertinib, which possess elevated levels of ACK1, and the growth of osimertinib-resistant tumors in vivo. " 06/01/2020 - "Osimertinib is effective in T790M-mutant cancers, but not against those exhibiting the subsequent C797S mutation. " 01/01/2019 - "Osimertinib is basically effective for tumors that acquire resistance to EGFR-TKIs as a result of T790M mutation. "
5.	Adenocarcinoma of Lung 01/01/2021 - "Here, we report the case of a Chinese patient with lung adenocarcinoma (LADC) harboring a T790I mutation who achieved significant benefits from osimertinib treatment." 08/01/2019 - "These findings suggest that osimertinib is beneficial for lung adenocarcinoma patients with squamous cell transformation harboring the T790M mutation." 06/01/2021 - "We found that the first-line treatment with osimertinib was safe and resulted in a long-term response in elderly patients with de novo EGFR T790M-mutated lung adenocarcinoma." 04/12/2023 - "Here, we investigated the efficacy of two novel CDK12/13 inhibitors, AU-15506 and AU-16770, in osimertinib-resistant EGFR mutant lung adenocarcinoma cells in culture and xenograft models in vivo. " 10/01/2022 - "Efficacy of osimertinib in a metastatic lung adenocarcinoma patient harboring somatic EGFR delL747_S752 and germline BIM deletion polymorphism: a case report and literature review."

Related Drugs and Biologics

1.	ErbB Receptors (EGF Receptor)
2.	Tyrosine Kinase Inhibitors
3.	osimertinib
4.	Afatinib
5.	Erlotinib Hydrochloride (CP 358,774)
6.	Gefitinib (Iressa)
7.	Bevacizumab (Avastin)
8.	Platinum
9.	Epidermal Growth Factor (EGF)
10.	Pemetrexed (MTA)

Related Therapies and Procedures

1.	Therapeutics
2.	Drug Therapy (Chemotherapy)
3.	Radiotherapy
4.	Aftercare (After-Treatment)
5.	Adjuvant Chemotherapy